Drug Trial Radar · NCT06977841
Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial
Last checked: Nov 20, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
640
Actual
Start
Jun 10, 2025
Primary completion
Mar 10, 2026
Study completion Mar 10, 2026
Sponsor
- Lead sponsor
- Zhongshan Hospital (Xiamen), Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 18, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Current first-line Helicobacter pylori eradication protocols involve multidrug regimens comprising a proton pump inhibitor (PPI) or bismuth agent combined with dual antibiotics (e.g., clarithromycin, amoxicillin, quinolones, furazolidone, nitroimidazoles, or tetracycline) administered for 7-14 days. In China, the bismuth-containing quadruple therapy (BQT) remains the standard first-line treatment for H. pylori infection. However, BQT implementation is challenged by polypharmacy burdens, substantial adverse events, and suboptimal treatment adherence. Emerging evidence suggests that simplified dual therapies pairing acid suppressants (PPIs or potassium-competitive acid blockers \[P-CABs\]) with high-dose amoxicillin achieve comparable eradication rates to BQT while demonstrating superior tolerability and adherence profiles. Notably, the comparative efficacy of tetracycline-based versus amoxicillin-based dual regimens remains unexamined in controlled clinical trials. Our preliminary investigations established that optimized PPI-amoxicillin dual therapy achieves \>90% eradication rates in treatment-naïve populations. Building on these findings, this prospective randomized controlled trial will comparatively assess the effectiveness of tegoprazan-a novel P-CAB exhibiting potent acid inhibition-when co-administered with either amoxicillin or tetracycline in H. pylori-positive adults. The investigation aims to establish an evidence framework for streamlining eradication protocols through pharmacodynamic optimization while mitigating antimicrobial resistance development.
Conditions
- Helicobacter Pylori Eradication
- Adverse Reaction
Interventions
TegoprazanDrug
50 mg twice daily (BID), d1-14.
AmoxicillinDrug
In the Tegoprazan-Amoxicillin Dual Therapy group, amoxicillin 750 mg four times daily (QID) on days 1-14; in the Tegoprazan-Amoxicillin-Tetracycline Triple Therapy group and the Tegoprazan-Amoxicillin-Tetracycline-Bismuth Quadruple Therapy group, amoxicillin 1000 mg twice daily.
TetracyclineDrug
In the Tegoprazan-Tetracycline Dual Therapy group, tetracycline tablets 500 mg (Hainan Pharmaceutical Factory Co., Ltd. No. 1 Pharmaceutical Factory) were administered four times daily; in the Tegoprazan-Amoxicillin-Tetracycline Triple Therapy and Tegoprazan-Amoxicillin-Tetracycline-Bismuth Quadruple Therapy groups, tetracycline tablets 500 mg were administered three times daily.
BismuthDrug
In the Tegoprazan-Amoxicillin-Tetracycline-Bismuth Quadruple Therapy group, bismuth potassium citrate capsules 240 mg (Hunan Warner Pharmaceutical Co., Ltd.) were administered twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- H. pylori eradication rateTime frame: 44 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital (Xiamen), Fudan University
Xiamen, Fujian, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.